U.S. Markets closed

How Many Insiders Bought Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?

Veer Mallick

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell Obalon Therapeutics, Inc. (NASDAQ:OBLN), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, such insiders must disclose their trading activities, and not trade on inside information.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

Check out our latest analysis for Obalon Therapeutics

The Last 12 Months Of Insider Transactions At Obalon Therapeutics

In the last twelve months, the biggest single purchase by an insider was when Executive Chairman of the Board Andrew Rasdal bought US$200k worth of shares at a price of US$1.82 per share. That implies that an insider found the current (approximate) price enticing. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company’s future. We generally consider it a positive if insiders have been buying on market, even if the share price has increased a bit since then.

Over the last year, we can see that insiders have bought 556.97k shares worth US$1.1m. In total, Obalon Therapeutics insiders bought more than they sold over the last year. The average buy price was around US$1.96. It’s great to see insiders putting their own cash into the company’s stock, albeit at below the recent share price (US$2.13). You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGM:OBLN Recent Insider Trading, February 21st 2019

I will like Obalon Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Does Obalon Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Obalon Therapeutics insiders own about US$4.0m worth of shares (which is 8.3% of the company). We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Overall, this level of ownership isn’t that impressive, but it’s certainly better than nothing!

So What Does This Data Suggest About Obalon Therapeutics Insiders?

There haven’t been any insider transactions in the last three months — that doesn’t mean much. However, our analysis of transactions over the last year is heartening. The transactions are fine but it’d be more encouraging if Obalon Therapeutics insiders bought more shares in the company. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Obalon Therapeutics.

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.